Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis

Authors: Tanwarat Sanvoranart, Aungkura Supokawej, Pakpoom Kheolamai, Yaowalak U-pratya, Niphon Poungvarin, Sith Sathornsumetee, Surapol Issaragrisil

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Glioblastoma (GBM) is an aggressive malignant brain tumor that still lacks effective therapy. Glioblastoma stem cells (GBM-SCs) were identified to contribute to aggressive phenotypes and poor clinical outcomes for GBM. Netrin-1, an axon guidance molecule, has been found in several tumors in adults. However, the role of Netrin-1 in GBM-SCs remains largely unknown. In this study, CD133-positive U251 GBM cells were used as a putative GBM-SC population to identify the functions of Netrin-1. Using lentiviral transduction, Netrin-1 miR RNAi vectors were transduced into CD133-positive U251 cells. We demonstrated that cell proliferation and survival were decreased following targeted deletion of Netrin-1. Cell invasion was dramatically diminished in Netrin-1 knockdown GBM-SCs. Moreover, Netrin-1 knockdown GBM-SCs exhibited less proangiogenic activity. In conclusion, Netrin-1 may represent a therapeutic target in glioblastoma.
Appendix
Available only for authorised users
Literature
1.
Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–710.CrossRefPubMed
2.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the eortc-ncic trial. Lancet Oncol. 2009;10:459–66.CrossRefPubMed
3.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed
4.
Ostrom QT, Gittleman H, Liao P, et al. Cbtrus statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63.CrossRefPubMedPubMedCentral
5.
Urbanska K, Sokolowska J, Szmidt M, Sysa P. Glioblastoma multiforme—an overview. Contemp Oncol (Pozn). 2014;18:307–12.
6.
Bello MJ, Alonso ME, Aminoso C, et al. Hypermethylation of the DNA repair gene mgmt: association with tp53 g:C to a:T transitions in a series of 469 nervous system tumors. Mutat Res. 2004;554:23–32.CrossRefPubMed
7.
Kamiryo T, Tada K, Shiraishi S, et al. Correlation between promoter hypermethylation of the o6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery. 2004;54:349–57 .discussion 57CrossRefPubMed
8.
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.CrossRefPubMedPubMedCentral
9.
Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.CrossRefPubMed
10.
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.CrossRefPubMed
11.
Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193–206.CrossRefPubMed
12.
Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8.PubMed
13.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMed
14.
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell rna-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401.CrossRefPubMedPubMedCentral
15.
Meyer M, Reimand J, Lan X, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A. 2015;112:851–6.CrossRefPubMedPubMedCentral
16.
Johannessen TC, Wang J, Skaftnesmo KO, et al. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol. 2009;35:380–93.CrossRefPubMed
17.
18.
Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17:362–75.CrossRefPubMed
19.
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.CrossRefPubMed
20.
Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392–400.CrossRefPubMed
21.
Graef IA, Wang F, Charron F, et al. Neurotrophins and netrins require calcineurin/nfat signaling to stimulate outgrowth of embryonic axons. Cell. 2003;113:657–70.CrossRefPubMed
22.
Ming GL, Song HJ, Berninger B, et al. Camp-dependent growth cone guidance by netrin-1. Neuron. 1997;19:1225–35.CrossRefPubMed
23.
Serafini T, Kennedy TE, Galko MJ, et al. The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans unc-6. Cell. 1994;78:409–24.CrossRefPubMed
24.
Delloye-Bourgeois C, Brambilla E, Coissieux MM, et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst. 2009;101:237–47.CrossRefPubMed
25.
Dumartin L, Quemener C, Laklai H, et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology. 2010;138:1595–606 .606 e1-8CrossRefPubMed
26.
Paradisi A, Maisse C, Coissieux MM, et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc Natl Acad Sci U S A. 2009;106:17146–51.CrossRefPubMedPubMedCentral
27.
Qi Q, Li DY, Luo HR, et al. Netrin-1 exerts oncogenic activities through enhancing yes-associated protein stability. Proc Natl Acad Sci U S A. 2015;112:7255–60.CrossRefPubMedPubMedCentral
28.
Akino T, Han X, Nakayama H, et al. Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma. Cancer Res. 2014;74:3716–26.CrossRefPubMedPubMedCentral
29.
Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature. 2004;431:80–4.CrossRefPubMed
30.
31.
32.
Shimizu A, Nakayama H, Wang P, et al. Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of rhoa, cathepsin b, and camp-response element-binding protein. J Biol Chem. 2013;288:2210–22.CrossRefPubMed
33.
Ylivinkka I, Hu Y, Chen P, et al. Netrin-1-induced activation of notch signaling mediates glioblastoma cell invasion. J Cell Sci. 2013;126:2459–69.CrossRefPubMed
34.
Fitamant J, Guenebeaud C, Coissieux MM, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A. 2008;105:4850–5.CrossRefPubMedPubMedCentral
35.
Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–21.CrossRefPubMed
36.
Goffart N, Kroonen J, Rogister B. Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers (Basel). 2013;5:1049–71.CrossRef
37.
38.
Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69–82.CrossRefPubMed
39.
Wang W, Reeves WB, Pays L, et al. Netrin-1 overexpression protects kidney from ischemia reperfusion injury by suppressing apoptosis. Am J Pathol. 2009;175:1010–8.CrossRefPubMedPubMedCentral
40.
Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66:7843–8.CrossRefPubMed
41.
Tadagavadi RK, Wang W, Ramesh G. Netrin-1 regulates th1/th2/th17 cytokine production and inflammation through unc5b receptor and protects kidney against ischemia-reperfusion injury. J Immunol. 2010;185:3750–8.CrossRefPubMed
42.
Tsuchiya A, Hayashi T, Deguchi K, et al. Expression of netrin-1 and its receptors dcc and neogenin in rat brain after ischemia. Brain Res. 2007;1159:1–7.CrossRefPubMed
43.
Mehlen P, Guenebeaud C. Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol. 2010;22:46–54.CrossRefPubMed
44.
Forcet C, Stein E, Pays L, et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent mapk activation. Nature. 2002;417:443–7.CrossRefPubMed
45.
Shekarabi M, Moore SW, Tritsch NX, et al. Deleted in colorectal cancer binding netrin-1 mediates cell substrate adhesion and recruits cdc42, rac1, pak1, and n-wasp into an intracellular signaling complex that promotes growth cone expansion. J Neurosci. 2005;25:3132–41.CrossRefPubMed
46.
Liu G, Beggs H, Jurgensen C, et al. Netrin requires focal adhesion kinase and src family kinases for axon outgrowth and attraction. Nat Neurosci. 2004;7:1222–32.CrossRefPubMedPubMedCentral
47.
Rajasekharan S, Bin JM, Antel JP, Kennedy TEA. Central role for rhoa during oligodendroglial maturation in the switch from netrin-1-mediated chemorepulsion to process elaboration. J Neurochem. 2010;113:1589–97.PubMed
48.
Lepekhin EA, Eliasson C, Berthold CH, et al. Intermediate filaments regulate astrocyte motility. J Neurochem. 2001;79:617–25.CrossRefPubMed
49.
Hagemann C, Anacker J, Ernestus RI, Vince GHA. Complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol. 2012;3:67–79.CrossRefPubMedPubMedCentral
50.
Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803:3–19.CrossRefPubMed
51.
McCready J, Broaddus WC, Sykes V, Fillmore HL. Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer. 2005;117:781–5.CrossRefPubMed
52.
Komatsu K, Nakanishi Y, Nemoto N, et al. Expression and quantitative analysis of matrix metalloproteinase-2 and −9 in human gliomas. Brain Tumor Pathol. 2004;21:105–12.CrossRefPubMed
53.
Wang M, Wang T, Liu S, et al. The expression of matrix metalloproteinase-2 and −9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003;20:65–72.CrossRefPubMed
54.
Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3:489–501.CrossRefPubMed
55.
Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin b and mmp-9 gene expression in glioblastoma cell line via rna interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene. 2004;23:4681–9.CrossRefPubMed
56.
Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin b, plasmin and kallikrein, and spontaneous activation. Biochem J. 1977;166:21–31.CrossRefPubMedPubMedCentral
57.
Tu T, Zhang C, Yan H, et al. Cd146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res. 2015;25:275–87.CrossRefPubMedPubMedCentral
Metadata
Title
Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis
Authors
Tanwarat Sanvoranart
Aungkura Supokawej
Pakpoom Kheolamai
Yaowalak U-pratya
Niphon Poungvarin
Sith Sathornsumetee
Surapol Issaragrisil
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5314-5

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Original Article

The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma

Review

Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment

Review

The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression

Original Article

The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo

Original Article

A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways

Original Article

High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits